Cardiovascular System Disease

Categories: Blood diseases, Cardiovascular diseases, Immune diseases

Aliases & Classifications for Cardiovascular System Disease

MalaCards integrated aliases for Cardiovascular System Disease:

Name: Cardiovascular System Disease 12 15
Disease of Subdivision of Hemolymphoid System 12
Abnormality of the Cardiovascular System 29
Disorder of Cardiovascular System 29
Cardiovascular Diseases 43
Cardiovascular Disease 17


External Ids:

Disease Ontology 12 DOID:1287
ICD9CM 34 429.2
MeSH 43 D002318
NCIt 49 C2931
SNOMED-CT 67 49601007
ICD10 32 I51.6
UMLS 71 C0007222

Summaries for Cardiovascular System Disease

Disease Ontology : 12 A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis.

MalaCards based summary : Cardiovascular System Disease, also known as disease of subdivision of hemolymphoid system, is related to coronary heart disease 1 and familial hypercholesterolemia. An important gene associated with Cardiovascular System Disease is MIR210 (MicroRNA 210), and among its related pathways/superpathways are Adipogenesis and Folate Metabolism. The drugs Dimethyl fumarate and Azilsartan medoxomil have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and kidney, and related phenotypes are cardiovascular system and immune system

Wikipedia : 74 Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. CVD... more...

Related Diseases for Cardiovascular System Disease

Diseases in the Cardiovascular System Disease family:

Autoimmune Disease of Cardiovascular System

Diseases related to Cardiovascular System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1302)
# Related Disease Score Top Affiliating Genes
1 coronary heart disease 1 34.4 SERPINE1 NOS3 MIR145 INS IL6 CRP
2 familial hypercholesterolemia 34.1 NOS3 INS IL6 CRP APOE APOB
3 vascular disease 34.1 SERPINE1 REN NOS3 MIR145 MIR143 INS
4 tangier disease 33.8 APOE APOB APOA1 ALB
5 heart valve disease 33.6 REN CRP ALB ACE
6 abdominal obesity-metabolic syndrome 1 33.6 SERPINE1 NOS3 INS APOB ADIPOQ
7 abdominal obesity-metabolic syndrome quantitative trait locus 2 33.5 SERPINE1 INS IL6 CRP ADIPOQ
8 hyperlipidemia, familial combined, 3 33.5 INS APOE APOB APOA1 ADIPOQ
9 hyperlipoproteinemia, type iii 33.5 APOE APOB APOA1
10 hyperthyroidism 33.5 INS IL6 CRP ALB
11 arteriolosclerosis 33.4 REN APOE ALB ADIPOQ
12 platelet glycoprotein iv deficiency 33.4 INS APOE APOB
13 lipid metabolism disorder 33.4 SERPINE1 INS IL6 CRP APOE APOB
14 chronic kidney disease 33.3 SERPINE1 REN NOS3 INS IL6 CRP
15 pericardium disease 33.2 REN IL6 CRP ALB ACE
16 kidney disease 33.2 SERPINE1 REN NOS3 INS IL6 CRP
17 heart conduction disease 33.2 REN INS CRP ALB ACE
18 atherosclerosis susceptibility 33.2 SERPINE1 NOS3 INS IL6 CRP CDKN2B-AS1
19 prediabetes syndrome 33.1 INS IL6 CRP APOB ALB ADIPOQ
20 peripheral vascular disease 33.1 SERPINE1 NOS3 INS IL6 CRP APOB
21 hypercholesterolemia, familial, 1 33.1 NOS3 INS CRP APOE APOB APOA1
22 cerebrovascular disease 33.1 SERPINE1 REN INS IL6 CRP APOE
23 myocardial infarction 33.1 SERPINE1 REN NOS3 MIR210 INS IL6
24 hypertension, essential 33.1 SERPINE1 REN NOS3 MIR210 MIR145 MIR143
25 body mass index quantitative trait locus 11 33.0 SERPINE1 REN NOS3 MIR143 MIR10A INS
26 congestive heart failure 33.0 REN NOS3 INS IL6 CRP CDKN2B-AS1
27 sleep apnea 32.9 SERPINE1 REN NOS3 INS IL6 CRP
28 heart disease 32.9 SERPINE1 REN NOS3 MIR210 MIR145 INS
29 end stage renal disease 32.8 REN NOS3 INS IL6 CRP ALB
30 angina pectoris 32.8 NOS3 INS IL6 CRP APOA1 ADIPOQ
31 peripheral artery disease 32.8 NOS3 IL6 CRP CDKN2B-AS1 APOE APOB
32 pre-eclampsia 32.8 SERPINE1 REN NOS3 MIR210 INS IL6
33 hyperglycemia 32.7 SERPINE1 NOS3 INS IL6 APOB ALB
34 diabetes mellitus, noninsulin-dependent 32.7 SERPINE1 REN NOS3 INS IL6 CRP
35 intermediate coronary syndrome 32.7 MIR145 INS IL6 CRP APOB APOA1
36 non-alcoholic fatty liver disease 32.7 SERPINE1 INS IL6 CRP APOB APOA1
37 fatty liver disease 32.6 INS IL6 CRP APOB ALB ADIPOQ
38 arteries, anomalies of 32.6 SERPINE1 REN NOS3 MIR210 MIR145 MIR143
39 hypertriglyceridemia, familial 32.6 SERPINE1 INS APOE APOB APOA1
40 stroke, ischemic 32.6 SERPINE1 REN NOS3 IL6 CRP CDKN2B-AS1
41 osteoporosis 32.6 SERPINE1 NOS3 INS IL6 CRP APOE
42 aortic aneurysm 32.6 MIR145 IL6 HIF1A-AS1 CRP CDKN2B-AS1 APOE
43 lipoprotein quantitative trait locus 32.6 SERPINE1 REN NOS3 MIR145 IL6 CRP
44 pulmonary hypertension 32.6 SERPINE1 REN NOS3 IL6 CRP ALB
45 systemic lupus erythematosus 32.6 SERPINE1 NOS3 MIR210 INS IL6 CRP
46 hypothyroidism 32.5 SERPINE1 REN INS CRP APOE APOB
47 impotence 32.5 NOS3 INS ALB ACE
48 hyperuricemia 32.4 REN INS CRP APOE APOB ALB
49 microvascular complications of diabetes 3 32.4 REN MIR217 INS ALB ACE
50 hepatic lipase deficiency 32.4 APOE APOA1

Graphical network of the top 20 diseases related to Cardiovascular System Disease:

Diseases related to Cardiovascular System Disease

Symptoms & Phenotypes for Cardiovascular System Disease

MGI Mouse Phenotypes related to Cardiovascular System Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.1 ACE ADIPOQ ALB APOA1 APOB APOE
2 immune system MP:0005387 10 ACE ADIPOQ ALB APOB APOE CRP
3 adipose tissue MP:0005375 9.91 ACE ADIPOQ APOE IL6 INS NOS3
4 liver/biliary system MP:0005370 9.85 ACE ADIPOQ ALB APOA1 APOB APOE
5 muscle MP:0005369 9.56 ADIPOQ ALB APOB APOE IL6 INS
6 renal/urinary system MP:0005367 9.28 ACE ADIPOQ ALB APOE IL6 INS

Drugs & Therapeutics for Cardiovascular System Disease

Drugs for Cardiovascular System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 5271565 637568
Azilsartan medoxomil Approved, Investigational Phase 4 863031-21-4
Norethindrone Approved Phase 4 68-22-4 6230
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
Pantoprazole Approved Phase 4 102625-70-7 4679
Zofenopril Approved Phase 4 81872-10-8
Methimazole Approved Phase 4 60-56-0 1349907
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
alemtuzumab Approved, Investigational Phase 4 216503-57-0
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
11 Tomato Approved Phase 4
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
Nevirapine Approved Phase 4 129618-40-2 4463
Enfuvirtide Approved, Investigational Phase 4 159519-65-0 16130199
Indinavir Approved Phase 4 150378-17-9 5362440
Didanosine Approved Phase 4 69655-05-6 50599
Amprenavir Approved, Investigational Phase 4 161814-49-9 65016
Tipranavir Approved, Investigational Phase 4 174484-41-4 65027
Dipyridamole Approved Phase 4 58-32-2 3108
Ustekinumab Approved, Investigational Phase 4 815610-63-0
Ziprasidone Approved Phase 4 146939-27-7 60854
Altretamine Approved Phase 4 645-05-6 2123
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
Doxazosin Approved Phase 4 74191-85-8 3157
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Vancomycin Approved Phase 4 1404-90-6 14969 441141
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
Sodium citrate Approved, Investigational Phase 4 68-04-2
Colchicine Approved Phase 4 64-86-8 2833 6167
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
Insulin detemir Approved Phase 4 169148-63-4 5311023
Insulin glargine Approved Phase 4 160337-95-1
Calcium polycarbophil Approved Phase 4 126040-58-2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Rilonacept Approved, Investigational Phase 4 501081-76-1 104924
Sevelamer Approved Phase 4 52757-95-6
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
Travoprost Approved Phase 4 157283-68-6 5282226
Drospirenone Approved Phase 4 67392-87-4 68873
Tolvaptan Approved Phase 4 150683-30-0 216237
Ibuprofen Approved Phase 4 15687-27-1 3672

Interventional clinical trials:

(show top 50) (show all 8753)
# Name Status NCT ID Phase Drugs
1 Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI Unknown status NCT02012140 Phase 4 ticagrelor
2 A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease Unknown status NCT00133328 Phase 4 valsartan
3 Homocysteine Lowering and Atherosclerosis Reduction Trial (HART) Unknown status NCT00217178 Phase 4 Vitamins: Folic acid, B6, B12
4 Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines Unknown status NCT02797028 Phase 4 Allopurinol
5 HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study) Unknown status NCT00106886 Phase 4 Folic acid, vitamin B6 and B12 or placebo
6 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
7 Does Administration of Vitamin D in African Americans With Hypovitaminosis D and Type 2 DM Improve Inflammatory Markers of Cardiovascular Disease? Unknown status NCT01153243 Phase 4 Ergocalciferol;Placebo pill
8 Does Rosuvastatin Delay Progression of Atherosclerosis in People With HIV Infection at Moderate Cardiovascular Risk? A Multicentre Randomized, Double Blind Placebo-controlled Trial Unknown status NCT01813357 Phase 4 Rosuvastatin
9 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
10 Levosimendan Versus Dobutamine in Cardiopatic Patients Undergoing Major Non Cardiac Surgery Unknown status NCT02012946 Phase 4 Levosimendan;Dobutamine
11 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
12 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
13 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
14 Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being Unknown status NCT02796378 Phase 4 Training+Simvastatin+Q10-placebo;Training+Simvastatin-placebo+Q10-placebo;Training+Simvastatin+Q10
15 Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease Unknown status NCT01893996 Phase 4 Adalimumab;Placebo
16 Multicenter, Randomized Trial Designed to Evaluate the Applicability of the Guidelines of the Italian Society of Diabetology for the Prevention of Cardiovascular Diseases in Type 2 Diabetes Unknown status NCT01240070 Phase 4
17 Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4 Simvastatin or Atorvastatin;Enalapril;Aspirin or clopidogrel;Rimonabant
18 Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
19 Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance Unknown status NCT03574857 Phase 4 Metolazone Oral Tablet;Chlorothiazide Injection
20 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
21 Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics in Patients With Arterial Hypertension and Chronic Heart Failure Unknown status NCT02087332 Phase 4 Prolonged release Torasemide (Britomar);Torasemide (Diuver)
22 PPARGC1β And CNTN4 Genotype as a Pharmacogenetic Assay of Thrombosis and Bleeding Risks - a Cross-Over Controlled Trial of Aspirin in Individuals at Increased Cardiovascular Risk. Unknown status NCT02970604 Phase 4 Aspirin
24 Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial Unknown status NCT01319643 Phase 4 Oxygen
25 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
26 Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin Unknown status NCT03195153 Phase 4 Atorvastatin 80mg;ALLOPURINOL 300 MG;Atorvastatin 80mg AND allopurinol 300 mg
27 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
28 The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus Unknown status NCT02418884 Phase 4 rosuvastatin
29 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
30 Effects of Intensive Antihypertensive Therapies on the Risk of Stroke in Hypertensive Adults: A Prospective Randomized Open-Label Blinded-Endpoint Trial, a Feasibility Study Unknown status NCT02817503 Phase 4 Standard BP control;Moderate BP control;Intensive BP control
31 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
32 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
33 Efficacy and Safety of Ivabradine in Hemodialysed Patients With Increased Heart Rate Unknown status NCT01364077 Phase 4 Ivabradine;Placebo
34 Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4 candesartan;lercanidipine
35 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
36 Effect of Pitavastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Unknown status NCT02863185 Phase 4 Pitavastatin;Atorvastatin
37 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
38 Hemostasis Pad Using Chitosan After Invasive Percutaneous Procedures Unknown status NCT02954029 Phase 4
39 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Unknown status NCT00879060 Phase 4 spironolactone
40 A Strategy of Home Telehealth for Management of Congestive Heart Failure: STARTEL Unknown status NCT00247000 Phase 4
41 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
42 Randomized Clinical Study to Assess the Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias Unknown status NCT01717469 Phase 4
43 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
44 Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease Unknown status NCT02264743 Phase 4 Femoston Conti;EVOREL® CONTI
45 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
46 Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems Unknown status NCT00332904 Phase 4 propranolol;spironolactone
47 Phase 4 Study of Effects of ARB Compared With Diuretics in Hypertension Patients With High Cardiovascular Risks Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
48 Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia Unknown status NCT01010516 Phase 4 High-dose rosuvastatin;Statin plus fenofibrate;Statin plus niacin ER/laropiprant
49 Evaluate Efficacy and Safety of Extended Adjuvant Treatment With Letrozole in Postmenopausal Women With Hormone Receptor Positive Breast Cancer Who Have Completed 5 Years of Toremifene Unknown status NCT01072318 Phase 4 Letrozole
50 Antiatherogenic and Antimetabolic Effect of Curcumin in Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin

Search NIH Clinical Center for Cardiovascular System Disease

Cochrane evidence based reviews: cardiovascular diseases

Genetic Tests for Cardiovascular System Disease

Genetic tests related to Cardiovascular System Disease:

# Genetic test Affiliating Genes
1 Disorder of Cardiovascular System 29 ACE
2 Abnormality of the Cardiovascular System 29

Anatomical Context for Cardiovascular System Disease

MalaCards organs/tissues related to Cardiovascular System Disease:

Heart, Endothelial, Kidney, Testes, Bone, Liver, Breast

Publications for Cardiovascular System Disease

Articles related to Cardiovascular System Disease:

(show top 50) (show all 2958)
# Title Authors PMID Year
Intracellular delivery strategies for microRNAs and potential therapies for human cardiovascular diseases. 46
21045204 2010
MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. 46
20624982 2010
MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. 46
19786632 2009
miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. 46
19578358 2009
MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. 46
18417479 2008
Unraveling the genetic causes in large pedigrees with gout by whole‑exome sequencing. 61
32124961 2020
Citric acid-enhanced dissolution of polyphenols during soaking of different teas. 61
31506961 2019
A novel antioxidant Mito-Tempol inhibits ox-LDL-induced foam cell formation through restoration of autophagy flux. 61
30321700 2018
Screening key genes for abdominal aortic aneurysm based on gene expression omnibus dataset. 61
29439675 2018
Circular RNA WDR77 target FGF-2 to regulate vascular smooth muscle cells proliferation and migration by sponging miR-124. 61
29042195 2017
[Nursing care in elderly patients with cardiovascular disease]. 61
28976398 2017
Multi-scale Modeling of the Cardiovascular System: Disease Development, Progression, and Clinical Intervention. 61
27138523 2016
Farnesoid-X-receptor expression in monocrotaline-induced pulmonary arterial hypertension and right heart failure. 61
26392308 2015
[Hyperprolactinaemia and bone mineral density]. 61
26319389 2015
Elderly deaths in Ankara, Turkey. 61
24962235 2014
Association of adrenergic receptor gene polymorphisms in gallbladder cancer susceptibility in a North Indian population. 61
24556804 2014
Denervation of nerve terminals in renal arteries: one-year follow-up of interventional treatment of arterial hypertension. 61
24408071 2014
[Retrospective analysis of 190 cases of hospitalized patients with psoriasis]. 61
24384952 2013
[Biomarkers and risk factors of cardiovascular system disease in diabetes mellitus type 2]. 61
23951913 2013
No or only population-specific effect of PON1 on human longevity: a comprehensive meta-analysis. 54
20362697 2010
Atrial natriuretic peptide and oxidative stress. 54
20385186 2010
Residential traffic exposure, pulse pressure, and C-reactive protein: consistency and contrast among exposure characterization methods. 54
20123638 2010
Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase. 54
20205608 2010
Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease. 54
20096841 2010
ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study. 54
20189274 2010
Changes in the immune system during menopause and aging. 54
20515802 2010
Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. 54
20385972 2010
Dalcetrapib: a review of Phase II data. 54
20465364 2010
Neuropeptide Y and sleep. 54
20122859 2010
Adenoviral-mediated overexpression of DDAH improves vascular tone regulation. 54
20219849 2010
Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. 54
20515790 2010
Regulatory polymorphism in transcription factor KLF5 at the MEF2 element alters the response to angiotensin II and is associated with human hypertension. 54
20086047 2010
The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? 54
20124546 2010
Higher leptin levels in Asian Indians than Creoles and Europids: a potential explanation for increased metabolic risk. 54
20125099 2010
A significant decline in IGF-I may predispose young Africans to subsequent cardiometabolic vulnerability. 54
20215395 2010
ROCK2 associates with lectin-like oxidized LDL receptor-1 and mediates oxidized LDL-induced IL-8 production. 54
20181930 2010
Leptin-induced vascular smooth muscle cell proliferation via regulating cell cycle, activating ERK1/2 and NF-kappaB. 54
20458445 2010
The axis of thrombospondin-1, transforming growth factor beta and connective tissue growth factor: an emerging therapeutic target in rheumatoid arthritis. 54
19485899 2010
[Anti-diabetic drugs for secondary prevention of cardiovascular disease in mild diabetic and IGT patients: ABC study and PPAR study]. 54
20446588 2010
Association between apoliprotein E gene polymorphism and hypercholesterolemic phenotype in Maracaibo, Zulia state, Venezuela. 54
20019593 2010
Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin. 54
20064494 2010
The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. 54
20005515 2010
Soluble epoxide hydrolase in atherosclerosis. 54
20425256 2010
Endothelium-derived endothelin-1. 54
19967386 2010
Hepatocyte growth factor and the risk of ischemic stroke developing among postmenopausal women: results from the Women's Health Initiative. 54
20203323 2010
Comparison of cystatin C and creatinine as predictors of cardiovascular events in a community-based elderly population. 54
20207770 2010
Serum profiles of monocyte chemoattractant protein-1 as a biomarker for patients recovering from myocardial infarction. 54
20140679 2010
Cellular signaling and NO production. 54
20082095 2010
Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. 54
19922962 2010
Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. 54
20466987 2010

Variations for Cardiovascular System Disease

Expression for Cardiovascular System Disease

Search GEO for disease gene expression data for Cardiovascular System Disease.

Pathways for Cardiovascular System Disease

GO Terms for Cardiovascular System Disease

Cellular components related to Cardiovascular System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.14 SERPINE1 REN INS IL6 CRP APOE
2 high-density lipoprotein particle GO:0034364 9.63 APOE APOB APOA1
3 endoplasmic reticulum lumen GO:0005788 9.63 INS IL6 APOE APOB APOA1 ALB
4 very-low-density lipoprotein particle GO:0034361 9.61 APOE APOB APOA1
5 endocytic vesicle lumen GO:0071682 9.54 APOE APOB APOA1
6 low-density lipoprotein particle GO:0034362 9.5 APOE APOB APOA1
7 discoidal high-density lipoprotein particle GO:0034365 9.48 APOE APOA1
8 extracellular space GO:0005615 9.47 SERPINE1 REN MIR210 MIR143 MIR10A INS
9 chylomicron GO:0042627 9.43 APOE APOB APOA1
10 intermediate-density lipoprotein particle GO:0034363 9.13 APOE APOB APOA1

Biological processes related to Cardiovascular System Disease according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.98 IL6 APOE APOB APOA1 ALB
2 positive regulation of gene expression GO:0010628 9.97 NOS3 INS IL6 CRP CDKN2B-AS1 APOB
3 receptor-mediated endocytosis GO:0006898 9.92 APOE APOB APOA1 ALB
4 positive regulation of angiogenesis GO:0045766 9.9 SERPINE1 NOS3 MIR210 MIR143
5 negative regulation of inflammatory response GO:0050728 9.86 MIR145 APOE APOA1 ADIPOQ
6 negative regulation of angiogenesis GO:0016525 9.84 MIR217 MIR145 MIR143 MIR10A
7 retinoid metabolic process GO:0001523 9.82 APOE APOB APOA1
8 regulation of blood pressure GO:0008217 9.81 REN NOS3 ACE
9 positive regulation of blood vessel endothelial cell migration GO:0043536 9.79 NOS3 MIR210 MIR143
10 intermembrane lipid transfer GO:0120009 9.77 APOE APOB APOA1
11 acute-phase response GO:0006953 9.72 INS IL6 CRP
12 phospholipid efflux GO:0033700 9.69 APOE APOA1
13 negative regulation of smooth muscle cell proliferation GO:0048662 9.69 NOS3 MIR145 MIR143
14 angiotensin maturation GO:0002003 9.68 REN ACE
15 high-density lipoprotein particle clearance GO:0034384 9.68 APOE APOA1
16 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.68 APOA1 ADIPOQ
17 negative regulation of blood vessel diameter GO:0097756 9.68 INS CRP
18 negative regulation of lipid storage GO:0010888 9.67 IL6 CRP
19 angiotensin-activated signaling pathway GO:0038166 9.67 MIR145 MIR143
20 chylomicron remnant clearance GO:0034382 9.67 APOE APOB
21 very-low-density lipoprotein particle remodeling GO:0034372 9.66 APOE APOA1
22 positive regulation of cholesterol esterification GO:0010873 9.66 APOE APOA1
23 negative regulation of platelet activation GO:0010544 9.65 NOS3 APOE
24 negative regulation of hydrolase activity GO:0051346 9.65 NOS3 APOA1
25 neutrophil mediated immunity GO:0002446 9.65 IL6 ACE
26 regulation of Cdc42 protein signal transduction GO:0032489 9.63 APOE APOA1
27 very-low-density lipoprotein particle clearance GO:0034447 9.63 APOE APOB
28 lipoprotein metabolic process GO:0042157 9.63 APOE APOB APOA1
29 aorta smooth muscle tissue morphogenesis GO:0060414 9.61 MIR145 MIR143
30 lipoprotein catabolic process GO:0042159 9.61 APOE APOB
31 cholesterol efflux GO:0033344 9.61 APOE APOB APOA1
32 positive regulation of dendritic spine maintenance GO:1902952 9.58 INS APOE
33 positive regulation of cholesterol efflux GO:0010875 9.58 APOE APOA1 ADIPOQ
34 regulation of phenotypic switching GO:1900239 9.57 MIR145 MIR143
35 high-density lipoprotein particle remodeling GO:0034375 9.54 APOE APOA1 ALB
36 positive regulation of phospholipid efflux GO:1902995 9.52 APOE APOA1
37 positive regulation of lipid biosynthetic process GO:0046889 9.5 INS APOE APOA1
38 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.48 MIR145 MIR143
39 chylomicron assembly GO:0034378 9.43 APOE APOB APOA1
40 cellular protein metabolic process GO:0044267 9.43 INS IL6 APOE APOB APOA1 ALB
41 chylomicron remodeling GO:0034371 9.33 APOE APOB APOA1
42 lipoprotein biosynthetic process GO:0042158 8.8 APOE APOB APOA1

Molecular functions related to Cardiovascular System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.77 SERPINE1 REN APOE APOA1 ADIPOQ
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.55 MIR217 MIR210 MIR145 MIR143 MIR10A
3 lipid transporter activity GO:0005319 9.43 APOE APOB APOA1
4 lipoprotein particle binding GO:0071813 9.4 APOE APOA1
5 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.32 APOE APOA1
6 low-density lipoprotein particle receptor binding GO:0050750 9.13 CRP APOE APOB
7 intermembrane cholesterol transfer activity GO:0120020 8.8 APOE APOB APOA1

Sources for Cardiovascular System Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA